Cardiff Oncology (CRDF) Business Model - Discounting Cash Flows
Cardiff Oncology, Inc.
CRDF (NASDAQ)

Industry

Biotechnology

Sector

Healthcare

Number of Employees

31
Cardiff Oncology's Business Model

Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

About Cardiff Oncology

Website: https://www.cardiffoncology.com

CEO (Chief Executive Officer): Dr. Mark Erlander Ph.D.

IPO date: 2004-07-27

Contact

Country: US

Address: 11055 Flintkote Avenue

City: San Diego

State: CA

Phone: 858 952 7570

Zip Code: 92121

Other

CIK: 0001213037

ISIN: US14147L1089

CUSIP: 14147L108

discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us